GS
PTIXW

GTS Securities’s Protagenic Therapeutics Warrant PTIXW Stock Holding History

GTS Securities’s Portfolio PTIXW Stock Details PTIXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,300
Closed -$202 – 1521
2025
Q1 		$202 Sell
25,300
-100
-0.4% -$1 ﹤0.01% 1218
2024
Q4 		$76 Buy
25,400
+100
+0.4% +$1 ﹤0.01% 1216
2024
Q3 		$228 Hold
25,300
– – ﹤0.01% 4024
2024
Q2 		$202 Sell
25,300
-100
-0.4% -$2 ﹤0.01% 3873
2024
Q1 		$1.02K Buy
25,400
+200
+0.8% +$4 ﹤0.01% 3748
2023
Q4 		$378 Buy
+25,200
New +$489 ﹤0.01% 3981

Other funds holding PTIXW

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GTS Securities's PTIXW Position: Q2 2025 in Review

GTS Securities sold out of Protagenic Therapeutics Warrant (PTIXW) in Q2 2025, closing a stake of 25,300 shares — an estimated $202 sold.

GTS Securities first reported a position in PTIXW in Q4 2023 and held it in 6 quarters. The position peaked at $1.02K in Q1 2024. 4 funds tracked by Wall St. Rank hold PTIXW as of Q2 2025.

  • GTS Securities reported no remaining Protagenic Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 25,300 Protagenic Therapeutics Warrant shares in Q2 2025, an estimated $202.
  • GTS Securities first reported a position in Protagenic Therapeutics Warrant in Q4 2023 and held it in 6 quarters.
  • GTS Securities's Protagenic Therapeutics Warrant position peaked at $1.02K in Q1 2024.
  • 4 funds tracked by Wall St. Rank held Protagenic Therapeutics Warrant as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.